ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer

ABSTRACT: Small cell lung cancer (SCLC) represents ~15% of all lung cancers and is characterized by its highly aggressive phenotype and its dismal outcome. Though the addition of immune checkpoint blockade to carboplatin and etoposide treatment has improved outcome in SCLC patients, SCLC cells finally acquire the ability to evade immunosurveillance and resistance against immune check point blockade. To elaborate molecular mechanisms that mediate SCLC immune cell evasion we performed high dimensional profiling of human and murine SCLC specimens. We herein comprehensively analyzed matched human samples of primary and metastatic SCLC and found a loss of MHC-I in SCLC metastases indicating that MHC-I loss mediates SCLC immune cell evasion. Silencing MHC-I in SCLC cells drastically diminished immune cell infiltration and facilitated the formation of metastasis in mice by circumventing immune surveillance. Using mass spectrometry and phospho tyrosine kinase analysis we discovered that ERBB2 signaling suppresses MHC-I expression in SCLC cells and stimulates immune modulating transcripts. Mechanistically, genetic and/or pharmacologic blockade of the ERBB2 signaling axis was sufficient to induce MHC-I expression and to prevent immune evasion in autochthonous murine SCLC in a STING dependent manner. Finally, we demonstrate that ERBB2 signaling axis regulates MHC-I expression on SCLC cells and is critical in maintaining immune evasion in SCLC. Most strikingly, we here uncover synergistic treatment efficacy by combining ERBB2 with anti-PD-1 targeted treatment that elicits profound responses in preclinical SCLC models suggesting this combination for future clinical trials in patients with SCLC.

ORGANISM(S): Mus musculus

PROVIDER: GSE282715 | GEO | 2025/10/09

REPOSITORIES: GEO